The talk about the Detroit Tigers potentially trading Tarik Skubal hasn’t gone away, largely because every update coming out of Detroit suggests he’s tracking ahead of schedule in his return from elbow surgery. For a contender staring at an ace who might be back before the All-Star break, the idea of cashing in now for a monster deadline haul is an easy one to dream on.
But when you zoom out and look at the business side, the incentives point in a different direction. Skubal just had arthroscopic surgery to remove loose bodies from his left elbow, a procedure that typically sidelines pitchers for two to three months, even if it’s considered relatively simple. Early bullpen sessions and day to day quotes are encouraging, but front offices don’t trade for players based on optimism alone.
Any team acquiring him in July would be getting, at most, two months of regular-season innings plus a postseason run from a pitcher coming off an elbow procedure. That uncertainty suppresses his trade value. A healthy, in-his-prime, two-time Cy Young winner on an expiring deal is one kind of asset; that same pitcher with fresh elbow surgery is another, and GMs are going to price in downside risk whether the Tigers like it or not.
Detroit’s front office also knows it has a built‑in safety net after the season with the qualifying offer. Under MLB rules, the Tigers can extend Skubal a one-year contract at the league-determined qualifying offer rate — this winter that figure projects in the low‑20 million range — as long as he spends the whole year with them. If he rejects that offer and signs elsewhere, Detroit is guaranteed a compensatory draft pick in the next year’s draft.
Because the Tigers are classified as a revenue‑sharing recipient, that pick wouldn’t just be a throwaway late selection. Depending on the size of Skubal’s eventual contract, they’d land a choice between the first round and Competitive Balance Round A, or after Competitive Balance Round B — a meaningful piece of draft capital for an organization still balancing present contention with future depth. That’s a clean, predictable return that costs them nothing but the paper risk of Skubal surprising everyone by accepting the qualifying offer
Layer on the possibility of a post‑season lockout, and the calculus tilts even further toward patience. If labor talks stall and a lockout shuts down normal business, clubs will be looking even harder at cost‑controlled young talent and the value of extra draft picks once the system restarts. In that environment, holding Skubal through the season, extending the qualifying offer, and letting the market do its work just before or after a lockout becomes a logical way to convert an ace into a high draft asset without ever taking on the injury risk another team would need to discount.
Here the thing, folks: There’s also a softer, but real, business consideration here, the optics. Trading your homegrown, two‑time Cy Young winner in July while he’s working his way back from an elbow operation is a hard sell to a fan base, even for a robust package. Waiting allows the Tigers to market his return, sell some tickets, and still walk away with a premium pick when he inevitably chases a massive multi‑year deal in free agency.
With that . . . As Skubal ramps up and rumors flare with every positive bullpen report, the most likely outcome isn’t a blockbuster deadline deal. It’s Detroit playing the long financial game by riding the marketing wave of his comeback, extend the qualifying offer in November, and quietly pocket a valuable compensatory pick when their ace says no and signs his next contract somewhere else.
If you cannot play with them, then root for them!